Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status (Ascending)
62135-0250-24 62135-0250 Prednisolone oral Prednisolone 15.0 mg/5mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral May 31, 2024 In Use
62135-0760-01 62135-0760 Methylprednisolone Methylprednisolone 4.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral May 14, 2024 In Use
62135-0760-21 62135-0760 Methylprednisolone Methylprednisolone 4.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral May 14, 2024 In Use
62332-0730-31 62332-0730 METHOTREXATE METHOTREXATE 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral June 4, 2024 In Use
62332-0730-36 62332-0730 METHOTREXATE METHOTREXATE 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral June 4, 2024 In Use
65862-0390-10 65862-0390 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 12, 2010 In Use
65862-0390-19 65862-0390 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 12, 2010 In Use
65862-0390-30 65862-0390 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 12, 2010 In Use
65862-0390-05 65862-0390 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 12, 2024 In Use
65862-0391-01 65862-0391 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral March 24, 2021 In Use
65862-0391-10 65862-0391 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 12, 2010 In Use
65862-0391-30 65862-0391 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 12, 2010 In Use
65862-0391-66 65862-0391 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 12, 2010 In Use
65862-0391-02 65862-0391 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 12, 2024 In Use
65862-0391-05 65862-0391 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 12, 2024 In Use
46708-0730-31 46708-0730 METHOTREXATE METHOTREXATE 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral June 4, 2024 In Use
46708-0730-36 46708-0730 METHOTREXATE METHOTREXATE 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral June 4, 2024 In Use
67296-0902-01 67296-0902 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 31, 2007 In Use
67296-0902-02 67296-0902 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 1, 2021 In Use
67296-0902-03 67296-0902 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 31, 2007 In Use
68788-8433-01 68788-8433 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral April 24, 2024 In Use
68788-8433-03 68788-8433 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral April 24, 2024 In Use
68788-8433-06 68788-8433 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral April 24, 2024 In Use
68788-8433-09 68788-8433 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral April 24, 2024 In Use
68071-2661-00 68071-2661 PREDNISONE PREDNISONE 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral March 28, 2022 In Use

Found 10,000 results in 8 milliseconds — Export these results